Literature DB >> 8842452

Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.

G Fricker1, J Drewe, J Huwyler, H Gutmann, C Beglinger.   

Abstract

1. The interaction of cyclosporin A (CyA) with p-glycoprotein during intestinal uptake was investigated by a combination of in vitro experiments with human Caco-2 cells and an intubation study in healthy volunteers. 2. CyA uptake into the cells was not saturable and exhibited only a low temperature sensitivity, suggesting passive diffusion. When the permeation of CyA across Caco-2 monolayers from the apical to the basolateral side was determined, overall transport had an apparently saturable component up to a concentration of 1 microM. At higher concentrations permeation increased over-proportionally. Calculation of the kinetic parameters of apical to basolateral permeation suggested a diffusional process with a KD of 0.5 microliter min-1 per filter, which was overlayed by an active system in basolateral to apical direction with a KM of 3.8 microM and a Jmax of 6.5 picomol min-1 per filter. 3. CyA permeation was significantly higher when the drug was given from the basolateral side as compared to the permeation from the apical side. Apical to basolateral transport of CyA was increased in the presence of vinblastine, daunomycin and a non-immunosuppressive CyA-derivative. All compounds inhibit p-glycoprotein-mediated transport processes. Basolateral to apical permeation of CyA showed a dose-dependent decrease in the presence of vinblastine. Permeation of daunomycin across Caco-2 cell monolayers was also higher from the basolateral to the apical side than vice versa. Basolateral to apical permeation was decreased in the presence of SDZ PSC 833 and cyclosporin A. 4. Western blot analysis of Caco-2 cells with the monoclonal antibody C219 confirmed the presence of p-glycoprotein in the used cell system. 5. When the absorption of CyA in the gastrointestinal (GI)-tract of healthy volunteers was determined, a remarkable decrease of the plasma AUC could be observed dependent on the location of absorption in the rank order stomach > jejunum/ileum > colon. The decrease in absorption exhibited a marked correlation (r = 0.994) to the expression of mRNA for p-glycoprotein over the GI-tract (stomach < jejunum < colon). 6. All data provide evidence that CyA is a substrate of p-glycoprotein in the GI-tract, which might explain the local differences and the high variability in cyclosporin absorption found in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842452      PMCID: PMC1909843          DOI: 10.1111/j.1476-5381.1996.tb15612.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein.

Authors:  J Karlsson; S M Kuo; J Ziemniak; P Artursson
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

3.  Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators.

Authors:  J Hunter; M A Jepson; T Tsuruo; N L Simmons; B H Hirst
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

4.  Dose dependent absorption and linear disposition of cyclosporin A in rat.

Authors:  A Lindberg-Freijs; M O Karlsson
Journal:  Biopharm Drug Dispos       Date:  1994-01       Impact factor: 1.627

5.  Energy-dependent transport of digoxin across renal tubular cell monolayers (LLC-PK1).

Authors:  S Ito; G Koren; P A Harper; M Silverman
Journal:  Can J Physiol Pharmacol       Date:  1993-01       Impact factor: 2.273

6.  P-glycoprotein-mediated secretion of a fluorescent cyclosporin analogue by teleost renal proximal tubules.

Authors:  U Schramm; G Fricker; R Wenger; D S Miller
Journal:  Am J Physiol       Date:  1995-01

7.  Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.

Authors:  J Zacherl; G Hamilton; T Thalhammer; M Riegler; E P Cosentini; A Ellinger; G Bischof; M Schweitzer; B Teleky; T Koperna
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo.

Authors:  K V Speeg; A L Maldonado
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier.

Authors:  A Sakata; I Tamai; K Kawazu; Y Deguchi; T Ohnishi; A Saheki; A Tsuji
Journal:  Biochem Pharmacol       Date:  1994-11-16       Impact factor: 5.858

Review 10.  Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.

Authors:  B L Lum; G A Fisher; N A Brophy; A M Yahanda; K M Adler; S Kaubisch; J Halsey; B I Sikic
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860

View more
  36 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients.

Authors:  Steffen Bauer; Elke Störmer; Andreas Johne; Hagen Krüger; Klemens Budde; Hans-Hellmut Neumayer; Ivar Roots; Ingrid Mai
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

Review 3.  Coexistence of passive and carrier-mediated processes in drug transport.

Authors:  Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 4.  Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.

Authors:  Xianhua Cao; Seth T Gibbs; Lanyan Fang; Heather A Miller; Christopher P Landowski; Ho-Chul Shin; Hans Lennernas; Yanqiang Zhong; Gordon L Amidon; Lawrence X Yu; Duxin Sun
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

Review 5.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.

Authors:  J Alsenz; H Steffen; R Alex
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

Review 7.  Implications of pharmacogenetics for individualizing drug treatment and for study design.

Authors:  Christian Meisel; Thomas Gerloff; Julia Kirchheiner; Przemyslaw M Mrozikiewicz; Przemyslaw Niewinski; Jürgen Brockmöller; Ivar Roots
Journal:  J Mol Med (Berl)       Date:  2003-03-15       Impact factor: 4.599

8.  Association between MDR1 gene polymorphisms and the risk of Crohn's disease in a cohort of Algerian pediatric patients.

Authors:  Amira Bouzidi; Hamida Mesbah-Amroun; Aziza Boukercha; Fadila Benhassine; Réda Belboueb; Karima Berkouk; Wassila Messadi; Chafia Touil-Boukoffa
Journal:  Pediatr Res       Date:  2016-09-07       Impact factor: 3.756

Review 9.  Nanomedicines in renal transplant rejection--focus on sirolimus.

Authors:  Li-Jiuan Shen; Fe-Lin Lin Wu
Journal:  Int J Nanomedicine       Date:  2007

Review 10.  Population-based mechanistic prediction of oral drug absorption.

Authors:  Masoud Jamei; David Turner; Jiansong Yang; Sibylle Neuhoff; Sebastian Polak; Amin Rostami-Hodjegan; Geoffrey Tucker
Journal:  AAPS J       Date:  2009-04-21       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.